CH

Chemed Corporation

CHEHealthcareNASDAQ

Medical Care Facilities

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$2.53B
+4.1% YoY
Net Income
$265.2M
-12.2% YoY
EBITDA
$422.4M
-9.0% YoY
Free Cash Flow
$307.9M

Scan Results

Daily timeframe
DateIndicatorDetails
Aug 14 MACD Negative CrossoverHistogram -1.8929, negative momentum
Aug 13CONFIRMED MACD Negative CrossoverHistogram -1.0655, negative momentum
RSI OverboughtRSI 71.4, above 70, stock may be overbought
About Chemed Corporation

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers. The company carries a $6.79B market cap, placing it firmly in the mid-cap category. The company operates through two segments: VITAS and Roto-Rooter segments.

Where CHE stands vs its 150-day and 200-day moving averages

As of the August 14, 2026 close, CHE finished 21.48% above its 150-day moving average ($442.17) and 22.09% above its 200-day moving average ($439.98). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is CHE overbought or oversold?

At the August 14, 2026 close, CHE's RSI(14) was 65.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$6.79B
P/E (TTM)26.18
Fwd P/E18.89
EPS$19.86
Beta0.51
52W Change+12.3%
Dividend Yield0.54%
ROE27.1%
Analysis

The company holds $40.2M in cash, though total debt stands at $294.8M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $307.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 27.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 13.5% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $2.14B to $2.53B.

CHE's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CHE.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms